Prospective, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy with Pegylated Interferon, Ribavirin, and Boceprevir in Patients with Genotype 1 Chronic HCV with End Stage Renal Disease (ESRD) on Hemodialysis
Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) using trial drugs
Sponsor: Merck & Co. Inc
Enrolling: Male and Female Patients
IRB Number: AAAL5200
U.S. Govt. ID: NCT02112630
Contact: Theresa Lukose: 212-305-3839 /
Additional Study Information: The purpose of this study is to determine how safe and effective using three medications (pegylated-interferon, ribavirin and boceprevir) are in curing HCV in patients with end stage kidney disease on hemodialysis. Participants will be prescribed these three medications and will be followed closely through treatment, then for 6 months afterwards. During treatment, participants will need to come to clinic every 2 weeks through week 12, and then monthly until the end of treatment so that their doctor can monitor their progress on this treatment. Once participants have completed treatment, they will need to come in 1 month, 3 months and 6 months after the end of treatment.
This study is closed
Elizabeth Verna, MD
Do You Qualify?
Are you between 18-65 years of age? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Theresa Lukose